Bahrain becomes first nation to grant J&J COVID-19 shot emergency use

Vials of Johnson & Johnson's Janssen coronavirus disease (COVID-19) vaccine candidate are seen during the Phase 3 ENSEMBLE trial. (File/Reuters)

• Bahrain said it would dole out J&J’s shot to the most vulnerable people, including older adults
• The sate has logged 119,858 coronavirus infections and 437 deaths

DUBAI: Bahrain became the first nation to authorize Johnson & Johnson’s new single-dose coronavirus vaccine for emergency use on Thursday, the government announced, just a day after US regulators concluded the shot offers strong protection against severe COVID-19.
The island kingdom off the coast of Saudi Arabia said it would dole out J&J’s shot to the most vulnerable people, including older adults and those with chronic conditions, without specifying when. It was also unclear when doses would be delivered to the country, which already offers vaccines by state-backed Chinese firm Sinopharm, Pfizer-BioNtech and Oxford-AstraZeneca, as well as Russia’s Sputnik V to its roughly 2 million residents.
The move makes Bahrain’s health regulatory authority the first in the world to authorize the J&J vaccine for general use. In addition to the US, European regulators and the World Health Organization also are considering J&J’s vaccine. Worldwide, the company aims to produce around a billion doses by the end of the year.
Meriam Adhbi Al-Jalahma, chief of Bahrain’s regulatory body, said authorities had conducted “an in-depth study” on “all documents submitted by the company, which included the results of the clinical trials.”
The vaccine “provides a great protection against serious infection with COVID-19,” the statement added.
In an unusual move, South Africa started administering the J&J vaccine to health workers while it was still in testing. The country, where a virus variant is driving a new wave of infections, switched to J&J from AstraZeneca after a small study suggested it was poor at preventing mild to moderate COVID-19 caused by the more contagious variant.
The long-anticipated J&J shot promises to offer the US a third vaccine option and help speed vaccinations by requiring just one dose instead of two. Food and Drug Administration scientists confirmed that overall the vaccine is about 66% effective at preventing moderate to severe COVID-19, and about 85% effective against the most serious illness. The agency also said J&J’s shot is safe.
The tiny state of Bahrain has logged 119,858 coronavirus infections and 437 deaths. It boasts among the world’s fastest vaccination rates, with nearly 17% of the population having received at least one dose.